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ISSNObjective: This article compares the effects of initiating three contemporary antire-
troviral therapy (ART) regimens on progression of carotid artery intima–media thickness
(IMT) over 3 years.
Design: Randomized clinical trial.
Setting: Multicenter (26 institutions).
Patients: ART-naive HIV-infected individuals (n¼328) without known cardiovascular
disease or diabetes mellitus.
Intervention: Random assignment to tenofovir/emtricitabine along with atazanavir/
ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or raltegravir (RAL).
Main outcome measures: Right-sided carotid IMT was evaluated by B-mode ultra-
sonography before ART initiation, and then after 48, 96, and 144 weeks. Comparisons of
yearly rates of change in carotid IMT used mixed-effects linear regression models that
permitted not only evaluation of the effects of ART on carotid IMT progression but also
how ART-associated changes in traditional risk factors, bilirubin, and markers of HIV
infection were associated carotid IMT progression.
Results: HIV-1 RNA suppression rates were high in all arms (>85%) over 144 weeks.
Modest increases in triglycerides and non-high-density lipoprotein cholesterol levels
were observed in the protease inhibitor-containing arms compared with decreases with
RAL. In contrast, carotid IMT progressed more slowly on ATV/r [8.2, 95% confidence
interval (5.6, 10.8) mm/year] than DRV/r [12.9 (10.3, 15.5) mm/year, P¼0.013];
changes with RAL were intermediate [10.7 (9.2, 12.2) mm/year, P¼0.15 vs. ATV/r;
P¼0.31 vs. DRV/r]. Bilirubin and non-high-density lipoprotein cholesterol levels
appeared to influence carotid IMT progression rates.
Conclusion: In ART-naive HIV-infected individuals at low cardiovascular disease risk,
carotid IMT progressed more slowly in participants initiating ATV/r than those initiating
DRV/r, with intermediate changes associated with RAL. This effect may be due, in part,
to hyperbilirubinemia. Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2015, 29:1775–1783Keywords: antiretroviral therapy, atherosclerosis, cardiovascular disease,
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The relative contributions of antiretroviral therapy
(ART), traditional cardiovascular disease (CVD) risk
factors, inflammation, and immune activation on arterial
injury and atherosclerosis progression in HIV-infected
individuals are not known [1]. Previous observational
studies, including studies of carotid intima–media
thickness (IMT), have suggested that patients with
HIV infection are at increased risk for CVD [1,2]. Some
studies suggest that certain ART, including certain
protease inhibitors and abacavir, may cause increased
CVD risk in patients with HIV infection [3,4]. However,
differences in the prevalence of CVD risk factors among
individuals with HIV infection, which may partially be
related to ART, and the effects of persistent inflammation
and immune activation may also contribute to increased
CVD risk among individuals with HIV [5,6].
Newer ART regimens have less adverse metabolic effects
than older protease inhibitor-based regimens. For
example, both boosted darunavir (darunavir/ritonavir,
DRV/r) and boosted atazanavir (atazanavir/ritonavir,
ATV/r) are associated with less adverse lipid profiles, less
insulin resistance, and less lipodystrophy than older
protease inhibitor regimens [7–9]. Similarly, raltegravir
(RAL), an integrase inhibitor, has relatively neutral
metabolic effects [10,11]. These three modern ART
regimens were directly compared for virologic, toler-
ability and metabolic outcomes in AIDS Clinical Trials
Group study A5257 (ClinicalTrials.gov: NCT00851799
and NCT00811954), a prospective, randomized trial
[12]. Previous comparisons of the arterial effects of ART
have been limited by inclusion of individuals who
received prior ART. The present study – a predefined,
prospective substudy of A5257 – offered the unique
opportunity to isolate the effects of three modern ART
regimens from the persistent effects of previous ART.
The primary objective of this study was to compare the
effects of three contemporary ART regimens on carotid
IMT progression, a validated marker of carotid wall injury
and future CVD risk [13–15]. Carotid IMT is a common
surrogate endpoint in clinical trials of CVD risk reduction
such as those using lipid-lowering and antihypertensive
therapies [13–15]. Considering its antioxidant effects and
the increased incidence of hyperbilirubinemia among
individuals who take atazanavir, we also evaluated ( post
hoc) the effects of on-treatment bilirubin levels on carotid
IMT progression.Materials and methods
Study design
Study A5260s, a substudy of AIDS Clinical Trial Group
Study A5257, is a prospective, longitudinal evaluation of
ART-naı̈ve, HIV-infected individuals without known Copyright © 2015 Wolters Kluwer HCVD, diabetes mellitus, or use of lipid-lowering medi-
cations. Eligible A5257 participants were randomized
equally to one of the three regimens of tenofovir/
emtricitabine along with ATV/r, DRV/r, or RAL;
randomization was stratified by screening HIV RNA
level (>100 000 or100 000 copies/ml) and Framingham
10-year Coronary Heart Disease Risk Score (<6% or6%
risk). Substudy visits were scheduled at baseline, 4, 24, 48,
96, and 144 weeks after treatment initiation. Final substudy
visits could occur at any time between 112 and 144 weeks
after treatment initiation. Study A5260s as well as its parent
study, A5257, was approved by the Institutional Review
Boards of all 26 participating sites and all participants
provided written, informed consent (see Appendix A,
http://links.lww.com/QAD/A722). Current use of
statins, fish oil (>2 g/day), fibric acid derivatives, or niacin
(>1000 mg/day) was exclusionary at enrolment. Detailed
inclusion and exclusion criteria for the study were reported
previously in our baseline, cross-sectional analysis [16].
Carotid artery ultrasonography
B-mode images of the distal right common carotid artery
(CCA) and the right carotid artery bifurcation were
acquired with a high-resolution linear array ultrasound
transducer with simultaneous electrographic tracings
before ART initiation, and then after 48, 96, and
112–144 weeks [16]. The right CCA was imaged in
cross-section and the transducer moved laterally into the
jugular vein so they were stacked with the vein displayed
on top of the artery. The transducer was rotated 908,
maintaining the jugular vein stacked above the CCA and
bifurcation while obtaining a longitudinal view of both
the vessels, emphasizing the far wall. Images were sent
electronically to the University of Southern California
Atherosclerosis Research Unit Core Imaging and Read-
ing Center for quality control and interpretation by a
single experienced technician. Carotid artery ‘lesions’
were defined as focal regions of IMT of at least 1.5 mm.
The CCA and bifurcation were measured with a
proprietary automated edge detection program. Paired
ultrasound and phantom scans were obtained at baseline,
but within group, coefficient of variants was paired at
baseline CCA. The coefficients of variation for common
carotid IMT scans and paired baseline carotid bifurcation
IMT scans were 1.09 and 1.27%, respectively [16].
Brachial artery reactivity assessments
Brachial artery flow-mediated dilation (FMD) was
measured by ultrasound after induction of reactive
hyperemia by lower arm occlusion, prior to ART
initiation, and then after 4, 24, and 48 weeks, as described
previously [16]. These scans were measured at the
University of Wisconsin Atherosclerosis Imaging
Research Program Core Laboratory.
Laboratory and biomarker assessments
Blood samples were obtained from participants who were
required to fast for at least 8 h and sent to core laboratoriesealth, Inc. All rights reserved.

























Fig. 1. (a) Change in common carotid artery intima–media
thickness progression by study week (intention to treat). (b)
Change in carotid artery bifurcation intima–media thickness
progression by study week (intention to treat). Point esti-
mates and error bars give mean and 95% confidence intervals,
respectively. ATV/r, atazanavir/ritonavir; DRV/r, darunavir/
ritonavir; RAL, raltegravir.for analyses, as described previously [16]. Lipoproteins as
well as GlycA and GlycB were quantified by nuclear
magnetic resonance spectroscopy at LipoScience
(Raleigh, North Carolina, USA). Inflammatory bio-
markers were measured at the University of Vermont
Laboratory for Clinical Biochemistry on plasma stored at
708C. These measures included high-sensitivity C-
reactive protein (hsCRP) by nephelometry (Siemens
BNII Nephelometer; Siemens Healthcare, Indianapolis,
Indiana, USA), interleukin-6, and D-dimer. Plasma
markers of monocyte and immune activation (soluble
CD14 and CD163) were determined using ELISA (R&D
Systems, Minneapolis, Minnesota, USA).
Peripheral blood mononuclear cells were isolated and
cryopreserved within 30 h of blood collection. All
specimens were stored in liquid nitrogen at 708C.
Immunophenotyping was performed on cryopreserved
peripheral blood mononuclear cells using multicolor flow
cytometry. The fluorochrome-conjugated antibodies
used were anti-CD3 PE-Cy7 (clone SK7), anti-CD8
APC (clone RPA-T8), anti-HLADR FITC (clone
L243), anti-CD38 PE (clone HB7), anti-CD14 APC
(clone M5E2), anti-CD16 PE-Cy7 (clone 3G8) (BD
Biosciences, San Jose, California, USA, and Invitrogen,
Carlsbad, California, USA). Samples were acquired on an
LSR-II flow cytometer Fluorescence Minus One and
controls were prepared on controls for each run.
Monocytes were gated as DUMP (CD2, CD3, CD19,
CD20, and CD56) negative; HLADR-positive cells and
proinflammatory monocytes were characterized and
expressed as proportional percentages (CD14þ,
CD16þ) as previously described. T-cell activation
(CD4þCD38þDRþ and CD8þCD38þDRþ) was
measured by flow cytometry. Data were compensated
and analyzed in FlowJo software, version 9.3.3 (Treestar,
Ashland, Oregon, USA).
Sample size considerations and statistical
analysis
The primary hypothesis was that progression of right
CCA IMTwould be faster over 144 weeks in participants
initiating a ritonavir-boosted protease inhibitor-contain-
ing regimen compared with a RAL-containing regimen.
The target sample size of 110 participants/group provided
80% power to detect a difference in the rate of CCA IMT
progression between the pooled-protease inhibitor regi-
mens and RAL of 1.3 mm/year. In the event of a
significant difference between ATV/r and DRV/r, the
study was designed to examine all pairwise treatment
group comparisons.
Primary treatment group comparisons used an intention-
to-treat approach; supportive analyses were restricted to
on-treatment and successfully treated populations
(Fig. 1). All analyses of IMT outcomes used mixed-
effects linear regression model with random intercept and
slope and unstructured covariance matrix on the random Copyright © 2015 Wolters Kluweeffect and adjusted for stratification factors. The treatment
group effect of interest was the difference in the rate of
change (i.e. the slope) of IMT over time (i.e. the
interaction between the treatment group and time).
Given randomization, the primary analysis included week
0 IMT in the outcome vector; supportive analyses
included only on-treatment outcomes and adjusted for
baseline IMT measure. Similar treatment group com-
parisons for the endothelial function week 24 change
from baseline were conducted using linear regression
with adjustment for week 0 baseline brachial artery
diameter.
Associations between CCA IMT progression and
traditional CVD risk factors, HIV-related measures,
and other biomarkers were examined in analyses
restricted to the successfully treated cohort to minimize
confounding due to lack of control of HIV-1 viremiar Health, Inc. All rights reserved.
1778 AIDS 2015, Vol 29 No 14(Fig. 1). Baseline and early on-treatment (week 24 or 48)
biomarker effects on both the level and rate of CCA IMT
progression were included as continuous outcomes; time-
updated proximal effects were also examined. To explore
the potential of treatment-mediated pathways, analyses
were also performed with adjustment for the treatment
group. Attenuation of the estimated treatment group
differences would be expected if treatment group
differences were mediated by given biomarker changes.
To explore the potential that ATV/r-associated hyperbi-
lirubinemia mediated the effects of this regimen on CCA
IMT progression, we examined how adjustment for
bilirubin elevations impacted the estimated treatment
group differences. Specifically, early on-treatment bilir-
ubin levels were parameterized as binary cut points of 0.6,
0.8, and 1.0 mg/dl and on a continuous scale [17].
Inference for all treatment comparisons was assessed
against a type I error of 2.5% with 97.5% confidence
intervals; all other inference was performed at a 5% type 1 Copyright © 2015 Wolters Kluwer H





Age (years) 36 (28, 45)
Race/ethnicity
Non-Hispanic white 144 (44%)
Non-Hispanic black 105 (32%)
Hispanic 65 (20%)
Asian/other/more than one race 13 (4%)
10-year risk of hard coronary
artery diseaseb (%)
Low (<6%) 289 (88%)
Medium/high (6%) 39 (12%)
HIV-1 RNA (log10 copies/ml) 4.5 (4.0, 5.1)
CD4þ cell count (cells/ml) 349 (203, 455)
SBP (mmHg) 117 (108, 125)
DBP (mmHg) 74 (68, 80)
Fasting total cholesterol (mg/dl) 152 (133, 177)
Fasting triglycerides (mg/dl) 107 (78, 151)
Fasting HDL cholesterol (mg/dl) 37 (31, 45)




BMI (kg/m2) 25 (22, 28)
Waist circumference (cm) 88 (81, 98)
Metabolic syndrome 44 (13%)
Current smoker 124 (38%)
Total bilirubin (mg/dl) 0.50 (0.40, 0.60)
Brachial artery diameter (mm) 0.43 (0.39, 0.46)
Brachial artery flow-mediated dilation (%) 4.5 (3.0, 6.3)
Common carotid artery IMT (mm) 0.65 (0.59, 0.70)
Carotid artery bifurcation IMT (mm) 0.74 (0.65, 0.82)
Evidence of carotid lesions 28 (9%)
ATV/r, atazanavir/ritonavir; DRV/r, darunavir/ritonavir; HDL, high-density
panel measures are from samples that were centrally tested.
aMedians (first and third quartiles) or number (%).
bMyocardial infarction or death from coronary heart disease.error rate. Analyses were performed using SAS Version
9.2 (Cary, North Carolina, USA).Results
Participant characteristics
The 334 participants in A5260s were similar to those
enrolled in A5257 except for a smaller proportion of
females and blacks and slightly higher CD4þ cell count
(Supplemental Table S1, http://links.lww.com/QAD/
A722). Baseline participant characteristics for the 328
participants in the analysis population are in Table 1; no
notable treatment group imbalances were seen. The
Framingham coronary heart disease risk was estimated to
be at least 6%/10 years in 12% of participants; 13% had
metabolic syndrome and 9% had carotid lesions at baseline
(6% ATV/r, 8% RAL, 12% DRV/r). Eighty-four percent
completed study follow-up, and two participants died.
Final CCA IMT scans occurred more than 112 weeksealth, Inc. All rights reserved.
Treatment group
ATV/r (N¼109) RAL (N¼106) DRV/r (N¼113)
99 (91%) 94 (89%) 101 (89%)
10 (9%) 12 (11%) 12 (11%)
37 (31, 45) 36 (27, 44) 35 (27, 46)
53 (49%) 43 (41%) 48 (42%)
34 (31%) 34 (32%) 37 (33%)
20 (18%) 20 (19%) 25 (22%)
2 (2%) 8 (8%) 3 (3%)
96 (88%) 96 (91%) 97 (86%)
13 (12%) 10 (9%) 16 (14%)
4.6 (4.0, 5.1) 4.5 (4.1, 5.1) 4.5 (4.0, 4.9)
350 (211, 461) 343 (185, 445) 355 (207, 461)
117 (107, 124) 117 (107, 125) 117 (108, 125)
74 (68, 80) 74 (68, 80) 76 (68, 80)
153 (134, 178) 150 (135, 178) 150 (131, 172)
114 (86, 160) 105 (76, 150) 98 (74, 133)
36 (32, 43) 39 (32, 45) 37 (30, 47)
114 (96, 142) 111 (97, 136) 111 (89, 131)
91 (69, 109) 89 (74, 110) 88 (71, 107)
26 (23, 29) 24 (22, 28) 24 (22, 27)
92 (81, 100) 89 (82, 96) 86 (81, 95)
16 (15%) 14 (13%) 14 (12%)
44 (40%) 39 (37%) 41 (36%)
0.50 (0.40, 0.60) 0.45 (0.30, 0.60) 0.40 (0.40, 0.60)
0.43 (0.39, 0.46) 0.43 (0.39, 0.46) 0.43 (0.39, 0.46)
4.4 (3.2, 6.3) 4.3 (2.6, 5.9) 4.5 (3.1, 6.6)
0.66 (0.59, 0.72) 0.64 (0.58, 0.69) 0.64 (0.59, 0.70)
0.74 (0.65, 0.81) 0.72 (0.64, 0.83) 0.74 (0.66, 0.83)
7 (6%) 8 (8%) 13 (12%)
lipoprotein; IMT, intima–media thickness; RAL, raltegravir. All lipid
Antiretroviral therapy and carotid wall thickness Stein et al. 1779after starting treatment; 88% (N¼ 288) had a baseline and
at least 2 postentry scans.
HIV-1 RNA suppression rates were high in all arms
throughout the study (>85% through 144 weeks). The
virologic, immunologic, and metabolic responses to these
regimens and their side-effects in the parent study have
been reported elsewhere [12]. As in the parent study,
modest and sustained increases in non-high-density
lipoprotein (HDL) cholesterol and triglycerides levels
were observed with initiation of ATV/r and DRV/r that
were maintained over time, in contrast with decreases in
these parameters observed with RAL [12]. There were
trends toward increasing use of lipid medications in all
groups over the duration of the study with similar
numbers of participants on statins (two to five per group)
at the final visit.
Effects of treatment on carotid intima–media
thickness progression
Significant differences between treatment groups were
noted in the annual rate of change of the right CCA and
bifurcation IMT values (Table 2, Fig. 1). Patients
initiating ATV/r [8.2 (5.6, 10.8) mm/year] progressed
more slowly than those initiating DRV/r [12.9 (10.3,
15.5) mm/year, P¼ 0.013]. There was intermediate
progression for those initiating RAL [10.7 (9.2,
12.2) mm/year; P¼ 0.15 vs. ATV/r; P¼ 0.31 vs.
DRV/r]. The ATV/r benefit was more pronounced in
the on-treatment and successfully treated cohorts [6.6
(3.2, 10.0) mm/year with ATV/r compared with 12.8
(9.7, 15.9) mm/year with DRV/r, P¼ 0.007, and 10.2
(8.3, 12.2) mm/year with RAL, P¼ 0.044). Similar
findings were seen in the carotid bifurcation (Table 2,
Fig. 1b).
Associations of longitudinal CCA IMT progression with
baseline and early on-treatment risk factors, plasma Copyright © 2015 Wolters Kluwe
Table 2. Annualized rates of change in common carotid artery and carotid
treatment group comparisons.
CCA IMT (mm/year)a,c CCA IMT (mm/year)a
Estimated progression rates by treatment group (95% confidence intervals)
P
ATV/r 8.2 (5.6, 10.8) <0.001 7.9 (5.2, 10.6) <0
DRV/r 12.9 (10.3, 15.5) <0.001 12.6 (9.8, 15.3) <0
RAL 10.7 (9.2, 12.2) <0.001 10.4 (8.7, 12.1) <0
Estimated difference (first minus second arm) in progression rates (97.5%
P
ATV/r vs. DRV/r 4.7 (8.9, 0.4) 0.013 6.0 (11.0, 1.0) 0
ATV/r vs. RAL 2.8 (7.0, 1.5) 0.15 2.3 (7.4, 2.7) 0
DRV/r vs. RAL 1.9 (2.4, 6.2) 0.31 3.7 (1.4, 8.7) 0
ATV/r, atazanavir/ritonavir; CCA, common carotid artery; DRV/r, darunavi
bold are statistically significant.
aIntention to treat.
bSuccessfully treated cohort.
cAnalyses adjusted for screening HIV-1 RNA level and Framingham risk sc
dAnalyses adjusted for screening HIV-1 RNA level and Framingham risk sbiomarkers (hsCRP, interleukin-6, D-dimer, sCD14,
sCD163, GlycA, and GlycB), and measures of cellular
immune activation (%CD4þ: CD38þHLADRþ T cells,
%CD8þ: CD38þHLADRþT cells, and %CD14þCD16þ
monocytes) are shown in Table 3. With the exception of
weak evidence of associations suggesting faster CCA IMT
progression for higher levels of baseline Homeostasis
Model Assessment of Insulin Resistance (P¼ 0.06) and
hsCRP (P¼ 0.06), no associations between CCA IMT
progression and baseline risk factors or biomarkers were
apparent (P> 0.19). There was an association between
faster CCA IMT progression and higher on-treatment
(week 24) levels of non-HDL cholesterol (P¼ 0.011). This
association did not change upon adjustment for treatment
group and estimated treatment effects were unchanged
suggesting that the treatment group differences were not
mediated through the non-HDL cholesterol pathway. No
other associations between CCA IMT progression and
early on-treatment or time-updated (proximal) levels of
biomarkers were apparent (P> 0.12, Table 3).
Effects of treatment on carotid artery lesions and
brachial artery reactivity
New carotid lesions were uncommon. Among the 28
patients with evidence of lesions at baseline, 22 patients
(79%) were continually observed with evidence of lesions
at every study week thereafter. At the final visit, lesions
were apparent in similar proportions among 28 patients
(10% in the ATV/r, 15% in the DRV/r, and 7% in the
RAL groups). Rates of carotid IMT progression did not
differ after 48 (P¼ 0.97) and 96 weeks (P¼ 0.97) based
on the presence or absence of carotid lesions.
FMD did not change significantly within any treatment
arm (P> 0.35). No significant differences in FMD
between arms were noted at any study week (P> 0.28).
More than half of all patients in all treatment arms had
changes in FMD within 2% at each study week, 61% atr Health, Inc. All rights reserved.
artery bifurcation intima–media thickness by treatment group and





.001 6.6 (3.2, 10.0) <0.001 8.7 (5.6, 11.8) <0.001
.001 12.8 (9.7, 15.9) <0.001 14.7 (11.6,17.8) <0.001
.001 10.2 (8.3, 12.2) <0.001 11.5 (9.7, 13.3) <0.001
confidence intervals)c
P P P
.007 4.7 (9.0, 0.5) 0.013 6.2 (11.3, 1.1) 0.007
.30 2.7 (7.0, 1.5) 0.15 4.6 (9.7, 0.5) 0.044
.11 2.0 (2.3, 6.3) 0.30 1.6 (3.3, 6.5) 0.46
r/ritonavir; IMT, intima–media thickness; RAL, raltegravir. Values in
ores.
cores and baseline CCA IMT (mm).
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Table 3. Longitudinal common carotid artery intima–media thickness associations with baseline and week 24 or 48 biomarker in successfully
treated population.
Additional annualized rate of IMT (mm/year) per unit change in biomarker (95% confidence interval)
Baseline biomarkera Week 24 or 48 biomarkerb
P P
Homeostasis model assessment of insulin resistance (log10) 5.27 (0.29, 10.83) 0.06 1.56 (3.63, 6.74) 0.55
Non-high-density lipoprotein cholesterol (per 30 mg/dl) 1.24 (0.62, 3.09) 0.19 2.22 (0.52, 3.93) 0.011
D-dimer (log10 mg/ml) 1.97 (2.10, 6.04) 0.34 1.08 (2.92, 5.08) 0.60
High sensitivity C-reactive protein (log10 mg/ml) 3.93 (0.18, 8.04) 0.06 0.96 (4.29, 2.37) 0.57
Interleukin-6 (log10 pg/ml) 2.54 (4.29, 9.37) 0.46 2.27 (6.53, 1.98) 0.29
Soluble CD14 (log10 ng/ml) 3.03 (14.75, 20.81) 0.74 4.37 (14.39, 23.12) 0.65
Soluble CD163 (log10 ng/ml) 4.93 (3.36, 13.22) 0.24 0.36 (10.92, 11.64) 0.95
GlycA (mmol/l) 0.00 (0.03, 0.02) 0.94 0.01 (0.03, 0.02) 0.67
GlycB (mmol/l) 0.03 (0.04, 0.11) 0.37 0.03 (0.03, 0.09) 0.41
%CD4þ: CD38þHLADRþ T cells 0.07 (0.20, 0.06) 0.28 0.15 (0.34, 0.05) 0.15
%CD8þ: CD38þHLADRþ T cells 0.05 (0.18, 0.08) 0.45 0.12 (0.28, 0.03) 0.12
%CD14þCD16þ monocytes 0.05 (0.25, 0.15) 0.63 0.02 (0.14, 0.17) 0.83
IMT, intima–media thickness.
aAnalyses adjusted for screening HIV-1 RNA level and Framingham risk scores, baseline common carotid artery intima–media thickness (mm), and
baseline biomarker.
bAnalyses adjusted for screening HIV-1 RNA level and Framingham risk scores and baseline common carotid artery intima–media (mm).week 4, 56% at week 24, and 59% at week 48. Changes in
FMD after 4, 24, and 48 weeks were not associated with
48 and 96-week changes in CCA IMT. Brachial artery
diameters remained stable over time in all treatment
groups with median changes not exceeding 0.01 mm.
Effects of bilirubin elevations on carotid
intima–media thickness progression
Bilirubin elevations are common during treatment with
atazanavir. We hypothesized that the antioxidant effect
of asymptomatic increases in unconjugated bilirubin in
the ATV/r may contribute to slower progression of
carotid IMT [18]. As expected, total bilirubin levels
increased rapidly and remained elevated among individ-
uals assigned to ATV/r (Supplemental Figure S2, http://
links.lww. com/QAD/A722). In general, higher levels of
on-treatment bilirubin were associated with slower Copyright © 2015 Wolters Kluwer H
Table 4. Longitudinal common carotid artery intima–media
thickness associations with weeks 4 and 24 total bilirubin levels in
successfully treated population.
Difference in annual rates of
change (mm/year) with 95%
confidence interval
Bilirubin level at week 4a P
Continuous (mg/dl) 0.79 (2.77, 1.19) 0.43
> vs. 0.6 4.49 (8.30, 0.67) 0.021
> vs. 0.8 2.37 (6.47, 1.72) 0.25
> vs. 1.0 3.35 (7.68, 0.98) 0.13
Bilirubin level at week 24a P
Continuous (mg/dl) 1.13 (2.95, 0.69) 0.22
> vs. 0.6 4.21 (7.95, 0.47) 0.027
> vs. 0.8 2.61 (6.67, 1.46) 0.21
> vs. 1.0 3.38 (7.65, 0.88) 0.12
CCA, common carotid artery.
aAnalyses adjusted for screening HIV-1 RNA level and Framingham
risk scores and baseline CCA intima–media thickness (mm).progression of CCA IMT (Table 4). However, of all
the analyses performed, the only effects that reached
statistical significance were the weeks 4 and 24 bilirubin
levels using a binary cut point of 0.6 mg/dl (P¼ 0.021 and
0.027, respectively). Similar trends were seen for the
higher cut points of 0.8 and 1.0 mg/dl; however, these
results did not achieve statistical significance (P> 0.12).
Upon adjustment for weeks 4 and 24 bilirubin levels using
the 0.6 mg/dl cut point, the treatment group differences
in the rate of CCA IMT change between ATV/r and
DRV/r as well as between ATV/r and RAL were
attenuated with a loss of the previously described
statistical significance for the DRV/r arm comparisons;
this attenuation was not seen at the higher thresholds
(Table 4 and Supplemental Table S2, http://links.lww.
com/QAD/A722).Discussion
In this prospective, randomized clinical trial of 328 HIV-
infected individuals beginning their first ARTregimen, we
found that after 3 years, both CCA and carotid bifurcation
IMT progressed more slowly in participants initiating
ATV/r than those initiating DRV/r, with intermediate
changes associated with RAL, despite more salutary lipid
effects with RAL. These differences were more pro-
nounced in participants who remained successfully treated
on their randomized regimen for the study duration. The
mean differences in carotid IMT progression between the
ATV/r and DRV/r are clinically relevant and on the order
of one-half to one-third the effect of statin therapy in
patients with high cholesterol. Our data also suggest that
low-level hyperbilirubinemia may have affected CCA
IMT progression and mediated the ATV/r effect.ealth, Inc. All rights reserved.
Antiretroviral therapy and carotid wall thickness Stein et al. 1781It is unclear whether differences in ART regimens or
their metabolic effects influence CVD risk, in large part
because few randomized clinical trials assessing ART have
had a significant number of adverse CVD events due to
the young age of the participants and short duration of
follow-up [1]. Thus, evaluating the effects of ART on
surrogate endpoints that predict adverse CVD events is
necessary. This was the first prospective randomized
clinical trial to evaluate the effects of contemporary
ART on carotid IMT, a proven surrogate of CVD risk
in clinical trials in individuals without HIV infection
[13–15]. Patients were followed for up to 144 weeks
with high levels of drug compliance and data
availability, and although a greater number of partici-
pants discontinued ATV/r for tolerability than DRV/r
and RAL, the findings of our intention-to-treat
analysis were strengthened in the setting of successful
treatment.
We chose carotid IMT progression as a primary endpoint
for this study because it is a well established surrogate for
CVD risk and for evaluating the arterial and CVD risk
effects of preventive therapies such as lipid-lowering and
antihypertensive medications [13–15]. Although a recent
meta-regression suggested that carotid IMT progression is
not a strong marker of CVD risk in observational studies
[19], in clinical trials, a recent meta-analysis demonstrated
that for each 10 mm/year slower rate of carotid IMT, there
was an 18% lower odds for myocardial infarction [14].
Statin therapy was also associated with a 12 mm/year
lower rate of carotid IMT progression and a 52%
reduction in CVD events [13]. These findings strongly
support use of change in carotid IMT as a surrogate
endpoint of changes in CVD risk in treatment
intervention studies.
Our finding of a benefit of ATV/r over DRV/r was
unexpected. In fact, A5260s was originally designed with
the assumption of no difference in carotid IMT
progression between ATV/r and DRV/r and that these
arms would be pooled for comparison with participants
assigned to receive RAL. On assessment for baseline and
on-treatment risk factors and biomarkers associated with
carotid IMT progression, statistically significant associ-
ations were detected only with early (week 24) non-HDL
cholesterol levels and total blood bilirubin higher than
0.6 mg/dl. Furthermore, the adjustment for on-treatment
differences impacted the estimated treatment group
difference only for bilirubin levels. Although the bilirubin
analyses were exploratory, post hoc, and limited by almost
nonoverlapping bilirubin distributions between the
ATV/r compared with the DRV/r and RAL groups, it
is plausible that the ATV/r benefit was mediated by
bilirubin. Bilirubin is an antioxidant that improves
endothelial function and retards progression of athero-
sclerosis [20,21]. In a recent report from the National
Health and Nutrition Examination Survey, total bilirubin
levels were associated with total mortality in the United Copyright © 2015 Wolters KluweStates and values above 0.6 as well as values below 0.4 mg/
dl were significantly associated with mortality in models
fully adjusted for, among other factors, CVD, diabetes
mellitus, cancer, use of certain medications, kidney
function, and liver function as well as smoking, alcohol,
and BMI [17]. Owing to the fact that atherosclerosis
involves arterial oxidative stress, bilirubin has been
considered a possible target for as an antiatherosclerotic
agent. Further supporting this observation is our on-
treatment analysis that biases the study population
toward individuals with long-term ATV/r and thus
bilirubin exposure; it suggested an even greater ATV/r
benefit.
In this study, starting ART was not associated with
improvements in FMD after 4, 24, and 48 weeks. A
previous randomized clinical trial of ART-naive individ-
uals randomized to receive three class-sparing older ART
regimens demonstrated significant endothelial dysfunc-
tion that improved after 4 and 24 weeks in all ART arms
with successful treatment [22]. There were notable
differences between participants in A5152s and our study
with the appearance that our participants were healthier.
Compared with those in A5152s, our participants, prior
to ART initiation, had higher FMD (4.5 vs. 3.7%).
Indeed, the FMD in our study was similar to that
observed after 4 weeks of ART in A5152s. Our
participants also had higher average measures of HDL
cholesterol (39 vs. 31 mg/dl) and CD4þ cell count (349
vs. 245 cells/ml), and lower HIV RNA levels (4.5 vs.
4.8 log10 copies/ml). Of note, a more recent cross-
sectional study also demonstrated that neither use of
ATV/r nor total bilirubin levels were associated with
improved FMD in ART-treated and suppressed indi-
viduals [23].
Limitations
As there was no ART-experienced control group, the
generalizability of our findings to ART-experienced
patients is uncertain. As there were no HIV-infected but
untreated patients, regression to the mean for the FMD
results cannot be excluded. The participants in the study
on average were young, at low CVD risk, and only 10%
were females, so generalizability to older patients,
especially women, may be limited. Nevertheless, this is
the largest report with the longest follow-up describing,
to date, the effects of modern ARTon CVD risk among
treatment-naı̈ve HIV-infected individuals. This study is
relatively small and underpowered to detect modest risk
factor associations with carotid IMT progression as well as
the effects of elevated bilirubin levels among individuals
receiving ATV/r. The large number of sites may also have
introduced variability into the measures of carotid IMT
and FMD and may have obscured some relationships;
however, markers of variability were excellent. As few
individuals in the RAL and DRV/r groups had extreme
bilirubin elevations and because treatment group andr Health, Inc. All rights reserved.
1782 AIDS 2015, Vol 29 No 14extreme bilirubin elevations were collinear, these
associations require cautious interpretation. These
caveats, as well as the absence of a large distribution of
bilirubin levels within the ATV/r group precluded our
ability to definitively establish whether bilirubin
elevations contributed to the effect of atazanavir on
progression of carotid IMT.
Conclusion
Among treatment-naive individuals, carotid IMT pro-
gresses more slowly on ATV/r than DRV/r, with
intermediate changes in individuals receiving RAL,
despite its more salutary lipid effects. Low-level
hyperbilirubinemia seems to affect carotid IMT pro-
gression and may mediate some of the effect of ATV/r on
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